Description：siRNA to inhibit MED13L expression using RNA interferenceForm：Lyophilized powderGene Symbol：MED13LAlternative Names：KIAA1025; PROSIT240; THRAP2; TRAP240L; Mediator of RNA polymerase II transcription subunit 13-like; Mediator complex subunit 13-like; Thyroid hormone receptor-associated protein 2; Thyroid hormone receptor-associated protein complex 240 kDa component-like Entrez Gene (Human)： 23389; SwissProt (Human)： Q71F56; Purity：> 97%Directions for Use：We recommends transfection with 10 nM - 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For example, resuspend one tube of 5 nmol siRNA oligo in 250 μl of DEPC water to get a final concentration of 20 μM.Quality Control：Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.Components：We offers pre-designed sets of 3 different target-specific siRNA oligo duplexes of human MED13L gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot.Storage/Stability：Shipped at 4 °C. Store at -20 °C for one year.